Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer
Clinical trial NCT05263882 · UNKNOWN
Trial details
- NCT number
- NCT05263882
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-01
- Primary completion
- 2023-12-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.